日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

不可切除肝细胞癌患者一线接受乐伐替尼联合抗PD-1抗体治疗后器官特异性反应:一项回顾性分析

Huang, Cheng; Zhu, Xiao-Dong; Shen, Ying-Hao; Wu, Dong; Ji, Yuan; Ge, Ning-Ling; Chen, Ling-Li; Tan, Chang-Jun; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

放射学和甲胎蛋白反应预测肝细胞癌免疫疗法联合酪氨酸激酶抑制剂治疗后的病理完全缓解:一项多中心研究

Huang, Cheng; Zhu, Xiao-Dong; Shen, Ying-Hao; Xu, Bin; Wu, Dong; Ji, Yuan; Chen, Ling-Li; Song, Tian-Qiang; Zhang, Wei; Zeng, Zhi-Ming; Huang, Hua-Sheng; Wang, Kui; Huang, Lan-Qing; Chen, Yong-Jun; Yang, Yu-Chen; Zhou, Le-Du; Long, Guo; Zhao, Hai-Tao; Wang, Yun-Chao; Ge, Ning-Ling; Chen, Yi; Tan, Chang-Jun; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan

Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study

乐伐替尼联合抗程序性死亡受体-1抗体治疗肝细胞癌患者的有效性和安全性:一项真实世界队列研究

Xu, Ming-Hao; Huang, Cheng; Li, Mei-Ling; Zhu, Xiao-Dong; Tan, Chang-Jun; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan; Shen, Ying-Hao

The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma

在肝细胞癌患者中,术前接受乐伐替尼联合抗PD-1抗体全身治疗后行肝切除术与单纯肝切除术的安全性比较

Shen, Ying-Hao; Huang, Cheng; Zhu, Xiao-Dong; Xu, Ming-Hao; Chen, Zhao-Shuo; Tan, Chang-Jun; Zhou, Jian; Fan, Jia; Sun, Hui-Chuan

Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma.

西罗莫司可抑制肝细胞癌的生长和转移进展

Wang Zheng, Zhou Jian, Fan Jia, Tan Chang-Jun, Qiu Shuang-Jian, Yu Yao, Huang Xiao-Wu, Tang Zhao-You